Reverse switching to originator infliximab may be considered in patients with inflammatory bowel diseases experiencing new side effects or loss of response after switching to a CT-P13 biosimilar

Shaden Mahmmod  1     Hans-Paul Damiaan Schultheiss  1     Nofel Mahmmod  2     Adriaan C. Tan  3     Gerard Dijkstra  4     Herma H. Fidder  1    
1 UMC Utrecht,Utrecht,Netherlands
2 Antonius Ziekenhuis Gastroenterology,Zeist,Netherlands
3 Canisius Wilhelmina Hospital Dept. of Hepatogastroenterology,Nijmegen,Netherlands
4 UMC Groningen Gastroenterology and Hepatology,Groningen,Netherlands

UEG Week 2019

United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019

Login to access library content


Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Forgot your password?

Reset myUEG password

Social Sharing